Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← Seth Klarman, latest 13F

Seth Klarman · Q2 2017

Baupost Group

Portfolio at the end of Q2 2017, from the 13F filed August 11, 2017. See the filing on EDGAR ↗

CompanyWeightValueSharesPriceHeld sinceChange
Cheniere Energy LNG · history 11.5% $1.01B 20,726,340 $48.71 Q1 2014 Reduce 5%
Synchrony SYF · history 10.0% $873.6M 29,295,030 $29.82 Q3 2016 Add 66%
Viasat VSAT · history 10.0% $871.1M 13,158,137 $66.20 Q2 2013 or earlier No change
Colony NorthStar CLNS · history 7.7% $675.0M 47,905,461 $14.09 Q1 2017 No change
Allergan AGN · history 6.8% $591.3M 2,432,603 $243.09 Q1 2016 No change
Qorvo QRVO · history 6.5% $569.9M 9,000,000 $63.32 Q1 2017 Add 25%
Twenty-First Century Fox FOXA · history 6.2% $542.4M 19,137,469 $28.34 Q3 2015 No change
Antero Resources AR · history 5.2% $457.5M 21,170,996 $21.61 Q3 2014 Add 46%
Theravance Biopharma TBPH · history 4.2% $369.5M 9,273,991 $39.84 Q2 2014 No change
PBF Energy PBF · history 4.0% $350.0M 15,724,175 $22.26 Q3 2013 No change
Dell Technologies DELL · history 3.9% $345.4M 5,652,459 $61.11 Q3 2016 No change
Qualcomm QCOM · history 3.3% $288.0M 5,216,000 $55.22 Q1 2017 No change
Twenty-First Century Fox FOX · history 2.3% $202.8M 7,278,100 $27.87 Q3 2015 No change
Keryx Biopharmaceuticals KERX · history 2.1% $186.5M 25,791,678 $7.23 Q1 2014 No change
Express Scripts ESRX · history 1.9% $163.2M 2,556,891 $63.84 Q1 2017 Add 108%
Cardinal Health CAH · history 1.8% $158.2M 2,030,000 $77.92 Q4 2016 Add 97%
Veritiv VRTV · history 1.6% $137.0M 3,044,385 $45.00 Q3 2014 No change
Forward Pharma FWP · history 1.5% $129.4M 6,364,059 $20.33 Q4 2014 Add 14%
Avis Budget Group CAR · history 1.2% $109.1M 4,000,000 $27.27 Q2 2017 Buy
Atara Biotherapeutics ATRA · history 0.9% $75.0M 5,359,632 $14.00 Q4 2014 No change
Silver Run Acquisition II SRUN · history 0.8% $71.0M 8,820,736 $8.05 Q2 2017 Buy
ChipMOS IMOS · history 0.8% $69.4M 3,509,858 $19.77 Q2 2013 or earlier No change
Spirit Realty Capital SRC · history 0.8% $66.7M 9,000,000 $7.41 Q2 2017 Buy
Paratek Pharmaceuticals PRTK · history 0.7% $57.7M 2,394,498 $24.10 Q4 2014 Add 17%
GTY Technology GTYH.U · units · history 0.5% $46.0M 4,400,000 $10.46 Q4 2016 No change
Conyers Park Acquisition CPAA · history 0.5% $43.7M 3,712,500 $11.78 Q3 2016 No change
Novagold Resources NG · history 0.5% $43.3M 9,500,000 $4.56 Q2 2013 or earlier No change
Theravance Biopharma TBPH.CV · convertible notes · history 0.5% $40.4M 30,000,000 prn Q4 2016 No change
Permian Resources CDEV · history 0.4% $36.7M 2,407,153 $15.26 Q4 2016 No change
Cascadian Therapeutics CASC · history 0.4% $32.4M 8,721,079 $3.72 Q2 2016 No change
Atlanta Braves Holdings BATRK · history 0.4% $31.2M 1,303,482 $23.97 Q2 2016 Reduce 35%
Credit Acceptance CACC · history 0.3% $25.4M 98,700 $257.14 Q2 2016 Reduce 60%
Saban Capital Acquisition SCAC · history 0.3% $23.3M 2,326,500 $10.00 Q4 2016 No change
Sunrun RUN · history 0.2% $20.3M 2,848,082 $7.12 Q3 2015 No change
Innoviva INVA.CV · convertible notes · history 0.2% $15.5M 16,980,000 prn Q3 2014 Reduce 24%
American International Group AIG.WS · warrants · history 0.1% $7.5M 354,812 $21.08 Q2 2013 or earlier Reduce 72%
Trilogy Metals TMQ · history 0.1% $6.7M 10,600,758 $0.63 Q2 2013 or earlier No change
Orexigen Therapeutics OREX · history 0.1% $6.5M 2,226,839 $2.90 Q3 2015 No change
Conyers Park Acquisition CPAA.WS · warrants · history 0.0% $3.2M 1,237,500 $2.62 Q3 2016 No change
Saban Capital Acquisition SCAC.WS · warrants · history 0.0% $1.5M 1,163,250 $1.25 Q4 2016 No change
40 positions100.0%$8.75B

Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q1 2017, adjusted for stock splits.

Sector weighting

Sector weights in this 13F
Energy21.2%
Health care20.9%
Financials & real estate20.5%
Media & telecom18.8%
Technology15.1%
Industrials1.8%
Other1.2%
Materials0.6%

What changed from Q1 2017

← Q1 2017 Q3 2017 →